ZA200408436B - Method for producing pseudo islets. - Google Patents

Method for producing pseudo islets.

Info

Publication number
ZA200408436B
ZA200408436B ZA200408436A ZA200408436A ZA200408436B ZA 200408436 B ZA200408436 B ZA 200408436B ZA 200408436 A ZA200408436 A ZA 200408436A ZA 200408436 A ZA200408436 A ZA 200408436A ZA 200408436 B ZA200408436 B ZA 200408436B
Authority
ZA
South Africa
Prior art keywords
producing pseudo
pseudo islets
islets
producing
pseudo
Prior art date
Application number
ZA200408436A
Other languages
English (en)
Inventor
Yin Liang
Jian Zhu
Laurel Sweet
James N Livingston
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ZA200408436B publication Critical patent/ZA200408436B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
ZA200408436A 2002-03-22 2004-10-19 Method for producing pseudo islets. ZA200408436B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36672802P 2002-03-22 2002-03-22

Publications (1)

Publication Number Publication Date
ZA200408436B true ZA200408436B (en) 2005-10-19

Family

ID=28675278

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200408436A ZA200408436B (en) 2002-03-22 2004-10-19 Method for producing pseudo islets.

Country Status (12)

Country Link
US (1) US20040005299A1 (pt)
EP (1) EP1490474A4 (pt)
JP (1) JP2005527203A (pt)
KR (1) KR20050000375A (pt)
CN (1) CN1643134A (pt)
AU (1) AU2003215023A1 (pt)
BR (1) BR0308753A (pt)
CA (1) CA2474512A1 (pt)
MX (1) MXPA04007064A (pt)
PL (1) PL372313A1 (pt)
WO (1) WO2003082189A2 (pt)
ZA (1) ZA200408436B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2314694T3 (es) * 2004-07-28 2009-03-16 F. Hoffmann-La Roche Ag Factor 1 promotor de la insulina como elemento de referen-cia/marcador de la insuficiencia de celulas beta.
BR112013009299B1 (pt) * 2010-10-22 2022-02-01 Cell & Tissue Systems, Inc Método para preparar ilhotas pancreáticas
JP2016202172A (ja) * 2015-04-16 2016-12-08 国立大学法人京都大学 疑似膵島の製造方法
CN109957539A (zh) * 2017-12-14 2019-07-02 深圳先进技术研究院 一种人造胰岛组织及其制备和应用
CN109406769A (zh) * 2018-09-28 2019-03-01 李军 Akr在min6细胞中胰岛素分泌机制研究的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804178A (en) * 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US6001387A (en) * 1992-05-29 1999-12-14 The Reguents Of The University Of California Spin disk encapsulation apparatus and method of use
US5510263A (en) * 1993-04-05 1996-04-23 Desmos, Inc. Growth of pancreatic islet-like cell clusters
US5876742A (en) * 1994-01-24 1999-03-02 The Regents Of The University Of California Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method of preparation thereof
IL113484A0 (en) * 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US5679565A (en) * 1995-04-10 1997-10-21 The Regents Of The University Of California Method of preserving pancreatic islets
AU6496996A (en) * 1996-02-23 1997-09-10 Circle Biomedical, Inc. Novel artificial pancreas
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Also Published As

Publication number Publication date
KR20050000375A (ko) 2005-01-03
WO2003082189A2 (en) 2003-10-09
BR0308753A (pt) 2005-01-11
MXPA04007064A (es) 2004-10-29
CA2474512A1 (en) 2003-10-09
AU2003215023A1 (en) 2003-10-13
EP1490474A2 (en) 2004-12-29
JP2005527203A (ja) 2005-09-15
PL372313A1 (en) 2005-07-11
CN1643134A (zh) 2005-07-20
US20040005299A1 (en) 2004-01-08
WO2003082189A3 (en) 2003-11-27
EP1490474A4 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
EP1514928A4 (en) METHOD FOR CONSTRUCTING ANTIBODIES
EP1484384A4 (en) PROCESS FOR PRODUCING BIOCARBURANT
GB0203306D0 (en) Method
IL163465A (en) Method for immunizing plants against bacterioses
AU2003261191A8 (en) Methods for producing biopolymers
PL1697390T3 (pl) Sposób wytwarzania organoacylofosforynów
EP1625829A4 (en) METHOD FOR PRODUCING ECHOGRAMS
AU2003258070A8 (en) Electrodionization method
AU2003294691A8 (en) Method for producing leather
AU2003244440A1 (en) Method for producing granulates
GB0215034D0 (en) Architecture generation method
EG25498A (en) Method for producing (3-oxo-2.3-dihydro-1h-isoindol-1h-isoindol-1-yl)acetylguanidine derivatives
GB0205509D0 (en) Method
ZA200408436B (en) Method for producing pseudo islets.
ZA200301591B (en) Method for producing polyacrylic acid.
AU2003269047A8 (en) Method for making biochips
AU2003253813A8 (en) Method for colpoplasty
HK1133870A1 (en) Method for producing 4-pentafluoride-sulfanyl-benzoylguanidines
EP1556396A4 (en) METHOD OF PRODUCING 2-DESOXY-L-RIBOSE
SG116494A1 (en) Process for producing w-mercaptoalkylpyridine.
PL372169A1 (en) Method for producing gelatin
HU0301605D0 (en) Method for producing hihg-purity citalopram
GB0200865D0 (en) Method
AU2002367923A8 (en) Method for preparing 2-alkoxyphenoxyethanamines from 2-alkoxyphenoxyethylacetamides
AU2003249978A1 (en) Method for producing 1-methylcyclopropylguanidine